On 18 January 2005, DNDi, in association with MMV, TB Alliance, Oxfam and MSF, held a seminar in London aimed primarily at policy makers. The objective was to bring back on the table the critical need for support from the UK and European governments for R&D of new and improved drugs for neglected diseases. An open letter signed by these organizations, as well as Sir John Sulston, was sent to Tony Blair . A response has since been received and a UK Minister of Development has asked to set up a meeting with DNDi Executive Director Bernard Pecoul.
To read the letter please visit www.dndi.org
Home > DNDi, MMV, TB Alliance, Oxfam UK, MSF and Sir John Sulston co-sign an open letter to UK Prime Minister Tony Blair.
DNDi's clinical trial site in Um El Kher, Sudan, is up and running. It will be one of a 5-site trial of paromomycin to treat visceral leishmaniasis (VL) in East Africa. The first VL patient started treatment with paromomycin on
17 November 2004.
Other trial sites are Kassab Hospital, Gadaref State Sudan; Gondar and Arba Minch hospitals in Ethiopia; and Kenya Medical Research Institute (KEMRI) in Kenya. There are currently over 130 patients in the trial.www.dndi.org
Home > Paromomycin Clinical trials begin in Suda
The DNDi IP approach will be pragmatic, and decisions regarding the possible acquisition of patents, ownership and licensing terms will be made on a case by case basis... www.dndi.org
Home > About DNDi > DNDi's Intellectual Property Policy